Physician profile
Christopher D Mire
NPI 1457363475
$4,927.25
in general payments reported to CMS, 2019-2025
26 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $287 · 2021: $699 · 2022: $648 · 2023: $744 · 2024: $855 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765 · Education: $0.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.95 |
| Education | $0.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $697.33 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $635.31 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $585.03 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $500.94 | 2024-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $313.62 | 2021-2024 | |
| Vifor Pharma, INC. | $243.90 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $241.96 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $234.86 | 2019-2023 | Rayaldee |
| Akebia Therapeutics INC | $196.20 | 2019-2024 | Auryxia |
| Calliditas Therapeutics US INC. | $163.38 | 2023-2025 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $159.86 | 2025 | Amvuttra |
| Aurinia Pharma U.S., INC. | $153.60 | 2021-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.14 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $116.19 | 2020-2024 | Acthar |
| Ardelyx, INC. | $92.85 | 2024-2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $85.48 | 2023 | Nxstage System One, Liberty Select Cycler |
| Apellis Pharmaceuticals, INC. | $71.44 | 2025 | Empaveli |
| Glaxosmithkline, LLC. | $70.36 | 2021-2025 | Shingrix, Arexvy |
| Fresenius USA Marketing, INC. | $50.46 | 2021-2024 | Velphoro |
| Travere Therapeutics, INC. | $42.02 | 2023-2025 | |
| Daiichi Sankyo INC. | $33.52 | 2021 | |
| Mozarc Medical US LLC | $23.26 | 2025 | Palindrome |
| Alexion Pharmaceuticals, INC. | $20.97 | 2023 | Ultomiris |
| Genzyme Corporation | $20.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.17 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.